Autolus Therapeutics Plc Is A Clinical Stage Biopharmaceutical Company Based In Londonukwith Operations In Philadelphiausafounded In 2014 By Drmartin Pulethe Company Specializes In Next Generation Programmed T Cell Therapies For Cancer Treatmentunder The Leadership Of Ceo Christian Itinautolus Focuses On Developing Chimeric Antigen Receptorcart Cell Therapies That Target Hematological Malignancies And Solid Tumors The Company Has A Diverse Product Pipelineincluding Auto1Which Is In Phase 2 For B Cell Acute Lymphoblastic Leukemiaand Auto3Currently In Phase 1 2 For Solid Tumorsautolus Has In House Capabilities For T Cell Engineering And Productionand It Actively Collaborates With Healthcare Providers To Develop Patient Specific Therapiesthe Company Is Listed On Nasdaq Under The Ticker Autl And Aims To Address High Unmet Needs In Oncologyparticularly For Relapsed Or Refractory Blood Cancers
